David Inglefield

Popular Topics

Intellectual Property

David Inglefield’s articles from Oblon, McClelland, Maier & Neustadt, L.L.P are most popular:

with Inhouse Counsel
with readers working within the Chemicals, Insurance, Technology and Law Firm industries
within Intellectual Property topic(s)
in European Union, Europe and Middle East

DETAILS

United States

+1 703 413 3000

AUTHORS CONTENT

REGENXBIO, Inc. v. Sarepta Therapeutics: Recombinant DNA Molecule Patent-Eligibility Under 35 U.S.C. § 101

United States IP

Eye Therapies, LLC. v. Slayback Pharma, LLC: How Prosecution History Can Alter Phrase Interpretation

United States IP

US Synthetic Corp. v. International Trade Commission: Safeguarding Structure And Property Limitations In Composition-of-Matter Claims

United States Healthcare

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More